Xofigo

July 3, 2019

Adding Xtandi to Xofigo Does Not Raise Risk of Bone Issues in CRPC, Study Says

News

Metastatic castration-resistant prostate cancer (CRPC) patients who receive Xtandi (enzalutamide) plus Xofigo (radium-223) in a real-world setting do not experience more fractures or bone-related events than those given Xofigo alone, ... Read more

December 7, 2017

Safety Concerns Make Bayer Unblind Prostate Cancer Trial of Xofigo Combination

News

An Independent Data Monitoring Committee has asked Bayer to unblind a Phase 3 clinical trial of a Xofigo (radium-223)-based therapy for prostate cancer after data indicated more bone fractures in ... Read more

December 17, 2015December 17, 2015

Prostate Cancer Combo Therapy Starting a Phase 3 Global Trial

News

A new Phase 3 clinical study, the EORTC trial 1333, will compare the combination treatment of enzalutamide and RA-223, versus enzalutamide alone, in the overall survival of patients with castration-resistant prostate ... Read more

October 28, 2014October 28, 2014

Study Finds Radium-223 Effective in Prostate Cancer Treatment Independently of Docetaxel Use

News

A recent study titled “Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis ... Read more